Mauna Kea targets profitability by end-2027 after strong H1 sales growth

Reuters2026/07/21 15:45

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Mauna Kea reaffirmed its target to reach profitability by year-end 2027, citing a strengthened balance sheet and a solid H2 2026 system-sales pipeline.
H1 2026 sales rose to EUR 3.2 million from EUR 2.3 million, up 44% at constant exchange rates, led by Cellvizio adoption in U.S. pancreatic cysts.
Management forecast higher H2 2026 U.S. system sales, driven by pancreatic-cyst momentum, platform upgrade conversions, and seasonally stronger hospital capital spending.
CellTolerance growth remained a key expectation, with H1 sales of EUR 896,000 up 142% year over year, supported by rapid expansion in EMEA and ROW.
Liquidity runway was projected beyond 2027 including a new optional EUR 4 million shareholder-loan facility, supplementing EUR 5 million cash at end-2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mauna Kea Technologies SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20260721192112) on July 21, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Mauna Kea targets profitability by end-2027 after strong H1 sales growth

You may also like

Crypto prices